What is Aclaris Therapeutics Inc. (ACRS) Stock Return on Shareholders’ Capital?

Aclaris Therapeutics Inc. (NASDAQ: ACRS) stock fell -1.34% on Wednesday to $17.70 against a previous-day closing price of $17.94. With 0.27 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.34 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $18.11 whereas the lowest price it dropped to was $17.55. The 52-week range on ACRS shows that it touched its highest point at $18.96 and its lowest point at $9.26 during that stretch. It currently has a 1-year price target of $34.33. Beta for the stock currently stands at 0.58.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ACRS was down-trending over the past week, with a drop of -1.50%, but this was up by 7.21% over a month. Three-month performance dropped to -2.85% while six-month performance rose 46.52%. The stock gained 38.71% in the past year, while it has gained 21.73% so far this year. A look at the trailing 12-month EPS for ACRS yields -1.29 with Next year EPS estimates of -1.67. For the next quarter, that number is -0.45. This implies an EPS growth rate of -33.20% for this year and -19.30% for next year.

Float and Shares Shorts:

At present, 66.67 million ACRS shares are outstanding with a float of 60.26 million shares on hand for trading. On Oct 13, 2022, short shares totaled 3.87 million, which was 5.81% higher than short shares on Sep 14, 2022. In addition to Dr. Neal S. Walker D.O. as the firm’s Co-Founder, CEO & Director, Mr. Frank Ruffo serves as its Co-Founder, CFO , Sec. & Treasurer.

Institutional Ownership:

Through their ownership of 96.15% of ACRS’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 52.43% of ACRS, in contrast to 38.15% held by mutual funds. Shares owned by individuals account for 22.80%. As the largest shareholder in ACRS with 6.60% of the stake, RA Capital Management LP holds 4,398,453 shares worth 4,398,453. A second-largest stockholder of ACRS, BVF Partners LP, holds 3,976,543 shares, controlling over 5.96% of the firm’s shares. Rock Springs Capital Management L is the third largest shareholder in ACRS, holding 3,961,249 shares or 5.94% stake. With a 2.68% stake in ACRS, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 1,786,979 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 2.14% of ACRS stock, is the second-largest Mutual Fund holder. It holds 1,429,452 shares valued at 22.31 million. Biotech Growth Trust Plc holds 1.84% of the stake in ACRS, owning 1,226,378 shares worth 19.14 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ACRS since 6 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ACRS analysts setting a high price target of $38.00 and a low target of $26.00, the average target price over the next 12 months is $31.20. Based on these targets, ACRS could surge 114.69% to reach the target high and rise by 46.89% to reach the target low. Reaching the average price target will result in a growth of 76.27% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ACRS will report FY 2022 earnings on 03/14/2023. Analysts have provided yearly estimates in a range of -$1.36 being high and -$1.94 being low. For ACRS, this leads to a yearly average estimate of -$1.49. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Aclaris Therapeutics Inc. surprised analysts by $0.09 when it reported -$0.30 EPS against a consensus estimate of -$0.39. The surprise factor in the prior quarter was $0.05. Based on analyst estimates, the high estimate for the next quarter is -$0.43 and the low estimate is -$0.49. The average estimate for the next quarter is thus -$0.45.

Summary of Insider Activity:

Insiders traded ACRS stock several times over the past three months with 0 Buys and 9 Sells. In these transactions, 0 shares were bought while 151,074 shares were sold. The number of buy transactions has increased to 23 while that of sell transactions has risen to 21 over the past year. The total number of shares bought during that period was 336,011 while 373,005 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *



The 5 Best Inflation Stocks for 2022